Low Incidence of Community-Acquired Pneumonia among Human Immunodeficiency Virus--Infected Patients after Interruption of Pneumocystis carinii Pneumonia Prophylaxis

Eigenmann, Christina; Flepp, Markus; Bernasconi, Enos; Schiffer, Veronique; Telenti, Amalio; Bucher, Heiner; Wagels, Thomas; Egger, Martin; Furrer, Hansjakob
April 2003
Clinical Infectious Diseases;4/1/2003, Vol. 36 Issue 7, p917
Academic Journal
We compared the incidence of bacterial pneumonia among 336 patients who discontinued trimethoprim-sulfamethoxazole (TMP-SMX) as prophylaxis against Pneumocystis carinii pneumonia (PCP) with that among 75 patients who fulfilled the criteria for discontinuation but continued receiving prophylaxis. The difference in the overall incidence rates for the 2 groups (1.2 events per 100 person-years) was not statistically significant. Discontinuation of TMP-SMX prophylaxis against PCP is not associated with a significant increase in the incidence of bacterial pneumonia among patients with a sustained CD4 cell count increase to >200 cells/μL.


Related Articles

  • Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. Lim, Poh-Lian; Zhou, Jialun; Ditangco, Rossana A.; Law, Matthew G.; Sirisanthana, Thira; Kumarasamy, Nagalingeswaran; Chen, Yi-Ming A.; Phanuphak, Praphan; Lee, Christopher K. C.; Saphonn, Vonthanak; Oka, Shinichi; Zhang, Fujie; Choi, Jun Y.; Pujari, Sanjay; Kamarulzaman, Adeeba; Li, Patrick C. K.; Merati, Tuti P.; Yunihastuti, Evy; Messerschmidt, Liesl; Sungkanuparph, Somnuek // Journal of the International AIDS Society;2012, Vol. 15 Issue 1, p1 

    Background: Pneumocystis jiroveci pneumonia (PCP) prophylaxis is recommended for patients with CD4 counts of less than 200 cells/mm3. This study examines the proportion of patients in the TREAT Asia HIV Observational Database (TAHOD) receiving PCP prophylaxis, and its effect on PCP and...

  • Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia. Tark Kim; Sung-Han Kim; Ki-Ho Park; Oh Cho; Heungsup Sung; Mi-Na Kim; Sang-Ho Choi; Jin-Yong Jeong; Jun Woo; Yang Kim; Sang-Oh Lee // Journal of Infection & Chemotherapy;Oct2009, Vol. 15 Issue 5, p343 

    Abstract  There are limited data on the efficacy of alternative regimens for treating patients with pneumocystis pneumonia (PCP). We compared the efficacy of clindamycin-primaquine (C-P) with that of pentamidine as a secondline treatment for PCP. Among 91 patients receiving...

  • co-trimoxazole. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p200 

    An encyclopedia entry for "co-trimoxazole" is presented. It refers to an antibacterial drug which combines trimethoprim and sulfamethoxazole. It is now used to treat infections that cannot be treated with other drugs. It is mainly used to prevent and treat pneumocystis pneumonia in people with AIDS.

  • Preclinical Drug Discovery for New Anti-Pneumocystis Compounds. Cushion, Melanie T.; Walzer, Peter D. // Current Medicinal Chemistry;Jul2009, Vol. 16 Issue 20, p2514 

    Pneumocystis remains an important cause of fatal pneumonia (PCP) in HIV patients and other immunocompromised hosts. Preclinical drug discovery for agents active against PCP has been hindered in large part by the lack of a continuous in vitro growth system. Since approval in 1978, the combination...

  • Cotrimoxazole is generally used to manage Pneumocystis jiroveci pneumonia in children receiving chemotherapy.  // Drugs & Therapy Perspectives;May2008, Vol. 24 Issue 5, p9 

    Paediatric patients undergoing chemotherapy are at risk of developing pneumonia (PCP) and should receive PCP prophylaxis. Cotrimoxazole (trimethoprim-sulfamethoxazole) is the drug of choice for prophylaxis and treatment

  • Prevalence of Dihydropteroate Synthase Mutants in HIV-Infected South African Children with Pneumocystis jiroveci Pneumonia. Zar, H. J.; Alvarez-Martinez, M. J.; Harrison, A.; Meshnick, S. R. // Clinical Infectious Diseases;10/1/2004, Vol. 39 Issue 7, p1047 

    Background. Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia (PCP) is a major cause of mortality in human immunodeficiency virus (HIV)-infected infants in Africa, but the prevalence of mutations in the gene encoding dihydropteroate synthase (DHPS) in isolates from Africa has not...

  • Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. Helweg-Larsen, Jannik; Benfield, Thomas; Atzori, Chiara; Miller, Robert F. // Journal of Antimicrobial Chemotherapy (JAC);Dec2009, Vol. 64 Issue 6, p1282 

    Objectives: First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.

  • ‘Septrin psychosis’ among renal transplant patients with Pneumocystis jirovecii pneumonia. Walker, Lauren E.; Thomas, Sherine; McBride, Catherine; Howse, Matthew; Turtle, Lance C. W.; Vivancos, Roberto; Beeching, Nick J.; Beadsworth, Michael B. J. // Journal of Antimicrobial Chemotherapy (JAC);May2011, Vol. 66 Issue 5, p1117 

    Objectives To report on the temporal relationship between administration of trimethoprim/sulfamethoxazole to medically immunosuppressed HIV-negative renal patients with Pneumocystis jirovecii pneumonia (PCP) and the development of an acute psychosis. Methods We investigated a retrospective case...

  • Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice. Lobo, Maria Luísa; Esteves, Francisco; de Sousa, Bruno; Cardoso, Fernando; Cushion, Melanie T.; Antunes, Francisco; Matos, Olga // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for PcP. The efficacy of low doses of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics